CN Patent

CN103582648A — 乙型肝炎病毒(hbv)表达的调节

Assigned to GlaxoSmithKline LLC · Expires 2014-02-12 · 12y expired

What this patent protects

本发明公开用于减少HBV mRNA、DNA和蛋白质表达的反义化合物和方法。此类方法、化合物以及组合物适用于治疗、预防或改善HBV相关疾病、病症或病状。

USPTO Abstract

本发明公开用于减少HBV mRNA、DNA和蛋白质表达的反义化合物和方法。此类方法、化合物以及组合物适用于治疗、预防或改善HBV相关疾病、病症或病状。

Drugs covered by this patent

Qalsody (TOFERSEN) · Biogen Ma

Patent Metadata

Patent number: CN103582648A
Jurisdiction: CN
Classification: —
Expires: 2014-02-12
Drug substance claim: No
Drug product claim: No
Assignee: GlaxoSmithKline LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.